SCHEMBL1089867

SCHEMBL1089867

c1ccc2c(N3CCCCCC3)nc(NCCN3CCOCC3)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX1 Q96LB2 1/20 0.58
▸ KDM4E B2RXH2 7/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ LMNA P02545 6/20 0.56
▸ HPGD P15428 4/20 0.56
▸ HTT P42858 2/20 0.56
▸ TOP2A P11388 1/20 0.56
▸ BCHE P06276 1/20 0.54
▸ ACHE P22303 1/20 0.54
▸ ACP1 P24666 1/20 0.54
▸ NPC1 O15118 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ RAD52 P43351 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ PIK3R1 P27986 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1088997 1.00 MRGPRX1 (0.58) MRGPRX1KDM4EALDH1A1KMT2AMEN1
SCHEMBL1089070 1.00 MRGPRX1 (0.58) MRGPRX1KDM4EALDH1A1KMT2AMEN1
SCHEMBL1089550 0.99 MRGPRX1 (0.59) MRGPRX1KDM4EALDH1A1KMT2AMEN1
SCHEMBL1088592 0.93 KDM4E (0.63) MRGPRX1KDM4EALDH1A1KMT2ALMNA
SCHEMBL1089186 0.93 KDM4E (0.63) MRGPRX1KDM4EALDH1A1KMT2ALMNA
SCHEMBL1088850 0.93 KDM4E (0.63) MRGPRX1KDM4EALDH1A1KMT2ALMNA
SCHEMBL1089430 0.92 KDM4E (0.64) MRGPRX1KDM4EALDH1A1KMT2ALMNA
SCHEMBL1089359 0.92 MRGPRX1 (0.64) MRGPRX1KDM4EALDH1A1KMT2AMEN1
SCHEMBL1090823 0.92 MRGPRX1 (0.64) MRGPRX1KDM4EALDH1A1KMT2AMEN1
SCHEMBL1089640 0.92 MRGPRX1 (0.64) MRGPRX1KDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 — — US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 — — US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 — — US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 — — US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885KDM4E 2001/4885ALDH1A1 916/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885KDM4E 2001/4885ALDH1A1 916/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885KDM4E 2001/4885ALDH1A1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback